[
    [
        {
            "time": "",
            "original_text": "医药投向标|腾盛博药新冠中和抗体获批 西安新通科创板IPO获受理 鞍石生物完成超2亿美元A轮融资",
            "features": {
                "keywords": [
                    "腾盛博药",
                    "新冠中和抗体",
                    "西安新通",
                    "科创板IPO",
                    "鞍石生物",
                    "A轮融资"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药投向标|腾盛博药新冠中和抗体获批 西安新通科创板IPO获受理 鞍石生物完成超2亿美元A轮融资",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]